Can scans and DNA predict cancer treatment success?

NCT ID NCT07259915

Not yet recruiting Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to better predict how head and neck cancer responds to chemoradiotherapy. Researchers will use MRI, PET/CT scans, and blood/tumor DNA tests from 152 patients to build a combined prediction model. The goal is to identify which patients have a complete response within 12 months after treatment, potentially personalizing future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients will benefit from chemoradiotherapy, potentially avoiding ineffective treatments and their side effects.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to a direct benefit for participants, and the prediction model might not be accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)

Contacts and locations

Locations

Centre Henri Becquerel

Rouen, France
Centre Hospitalier Universitaire

Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.